Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
A Randomized, Double Blind, Placebo-Controlled study to assess the Safety, Local Tolerance,
and Pharmacokinetics of LT5001 drug product in Hemodialysis Patients with Uremic Pruritus